Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to $400000.0.

  • Myriad Genetics' Other Non Operating Income rose 15000.0% to $400000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $700000.0, marking a year-over-year increase of 60000.0%. This contributed to the annual value of $1.1 million for FY2024, which is 12500.0% up from last year.
  • According to the latest figures from Q3 2025, Myriad Genetics' Other Non Operating Income is $400000.0, which was up 15000.0% from -$100000.0 recorded in Q2 2025.
  • Myriad Genetics' Other Non Operating Income's 5-year high stood at $120.6 million during Q3 2021, with a 5-year trough of -$2.4 million in Q2 2023.
  • In the last 5 years, Myriad Genetics' Other Non Operating Income had a median value of $0.0 in 2021 and averaged $8.6 million.
  • In the last 5 years, Myriad Genetics' Other Non Operating Income surged by 763750.0% in 2021 and then tumbled by 250000.0% in 2023.
  • Quarter analysis of 5 years shows Myriad Genetics' Other Non Operating Income stood at $120.6 million in 2021, then plummeted by 99.59% to $500000.0 in 2022, then crashed by 240.0% to -$700000.0 in 2023, then soared by 142.86% to $300000.0 in 2024, then soared by 33.33% to $400000.0 in 2025.
  • Its Other Non Operating Income stands at $400000.0 for Q3 2025, versus -$100000.0 for Q2 2025 and $100000.0 for Q1 2025.